Table 2 Characteristics of patients with BCORMUT or BCORWT received decitabine therapy
Characteristics | BCORWT (n = 181) | BCORMUT (n = 14) | p value |
|---|---|---|---|
Age, median (range), year | 62 (17–85) | 62 (23–80) | 0.558 |
Gender, male:female, n (%) | 120:61 (66:34) | 7:7 (50:50) | 0.250 |
WHO/FAB classification, n (%) | Â | Â | 0.891 |
 RCMD | 47 (26.0) | 3 (21.4) |  |
 RAEB-1 | 57 (31.5) | 3 (21.4) |  |
 RAEB-2 | 39 (21.5) | 5 (35.7) |  |
 RAEB-t | 12 (6.6) | 1 (7.1) |  |
 CMML-1 | 17 (9.4) | 1 (7.1) |  |
 CMML-2 | 9 (5.0) | 1 (7.1) |  |
IPSS risk, n (%) | Â | Â | 0.858 |
 Intermediate-1 | 84 (46.4) | 7 (50.0) |  |
 Intermediate-2 | 77 (42.5) | 5 (35.7) |  |
 High | 20 (11.1) | 2 (14.3) |  |
Cytogenetic risk group, n (%) | Â | Â | Â |
 Good | 108 (59.7) | 12 (85.7) | 0.072 |
 Intermediate | 31 (17.1) | 2 (14.3) |  |
 Poor | 42 (23.2) | 0 |  |
Decitabine cycles, median (range), n | 4 (1–11) | 4 (2–7) | 0.411 |